FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg
daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the
signs and symptoms of benign prostatic hyperplasia (BPH)
2. To evaluate patient's tolerability to the use of FLOMAX® capsules 0.4 mg daily in
comparison to HYTRIN® capsules, 5 mg (with titration) daily for the treatment of the
symptoms of benign prostatic hyperplasia